Catalog No.
DHC90706
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LFB-R603, TG-1101, TGTX-1101, CAS: 1174014-05-1
Clone ID
Ublituximab
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia, PMID: 31558467
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis, PMID: 32351164
Ublituximab for the treatment of CD20 positive B-cell malignancies, PMID: 29609506
Antibodies to watch in 2020, PMID: 31847708
Antibodies to watch in 2021, PMID: 33459118
Antibodies to watch in 2019, PMID: 30516432
Immunotherapy in myasthenia gravis in the era of biologics, PMID: 30573759
Therapies for multiple sclerosis targeting B cells, PMID: 31044580
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2, PMID: 33411674
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis, PMID: 31994023
CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date, PMID: 31027436
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1, PMID: 33406479
B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients, PMID: 31077854
Anti-CD20 treatment for B-cell malignancies: current status and future directions, PMID: 32933335
A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder, PMID: 31232925
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial, PMID: 27982425
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial, PMID: 30709431
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial, PMID: 33631112
Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas, PMID: 23611989
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab, PMID: 28220479
The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia, PMID: 25552707
Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion, PMID: 23958919
Possible novel agents in marginal zone lymphoma, PMID: 28288710
Antibodies to watch in 2018, PMID: 29300693
Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis, PMID: 33551958
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era, PMID: 28499646
Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review, PMID: 32300434
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study, PMID: 34418815
B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report, PMID: 34364105
Antibodies to watch in 2017, PMID: 27960628
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives, PMID: 34382120
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders, PMID: 33419217
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis, PMID: 33516134
Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017, PMID: 28810856
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis, PMID: 34370283
Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages, PMID: 26307241
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues, PMID: 33880738
For research use only. Not for human or drug use.
